MedTrace Logo

Antiretroviral Improvement Among Medicaid Enrollees

NCT05477485 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2025-10-21

Study results available
· View outcomes & findings →

Summary

This study will evaluate whether a new program will affect how often human immunodeficiency virus (HIV) antiretroviral therapy (ART) prescriptions are filled and whether the program improves the health of people living with HIV.

Conditions

  • Human Immunodeficiency Virus

Interventions

BEHAVIORAL

Experimental: AIMS program - patient

Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by \>30 days. Support will come from the provider, pharmacy, managed care organization or the community. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) \>30-60 days. Support will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for \>60 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff and a confidential user community board.

OTHER

No Intervention/Usual care

Participants in the usual care arm will receive standard state-level care for late ART prescription refill(s) for Virginia Medicaid enrollees living with HIV.

Sponsors & Collaborators

  • Centers for Disease Control and Prevention

    collaborator FED

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Virginia Department of Medical Assistance Services - Virginia Medicaid

    collaborator UNKNOWN

  • Virginia Department of Health

    collaborator OTHER_GOV

  • University of Virginia

    collaborator OTHER

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • April D Kimmel, PhD · Virginia Commonwealth University

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-27
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05477485 on ClinicalTrials.gov